TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 2nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 4nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 8.5nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 11nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 33nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: <100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
Ligand Info
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: <100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
Ligand Info
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: <100nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: <100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
Ligand Info
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: <100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
Ligand Info
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: <100nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: <100nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: <100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
Ligand Info
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: <100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
Ligand Info
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: <100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
Ligand Info
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: <100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
Ligand Info
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: <100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
Ligand Info
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: <100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
Ligand Info
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: <100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
Ligand Info
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: <100nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: <100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
Ligand Info
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: <100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
Ligand Info
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: <100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
Ligand Info
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: <100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
Ligand Info
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: <100nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
Ligand Info
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 300nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
Ligand Info
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 300nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
Ligand Info
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 300nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
Ligand Info
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 300nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
Ligand Info
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 300nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
Ligand Info
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 300nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
Ligand Info
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 775nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 775nMAssay Description:The interaction of PD-1 and PD-L1 can be assessed using soluble, purified preparations of the extracellular domains of the two proteins. The PD-1 and...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 1.05E+3nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 1.05E+3nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 1.05E+3nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 1.05E+3nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 1.05E+3nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 1.05E+3nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 1.05E+3nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 1.05E+3nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 1.50E+3nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 3.50E+3nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 3.50E+3nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 3.50E+3nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 3.50E+3nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 3.50E+3nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 3.50E+3nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 3.50E+3nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair
TargetProgrammed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E](Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 3.50E+3nMAssay Description:The ability of the macrocyclic peptides of the present disclosure to bind to PD-L1 was investigated using a PD-1/PD-L1 Homogenous Time-Resolved Fluor...More data for this Ligand-Target Pair